Paradigm Biopharmaceuticals Limited
PBIGFOTCHealthcare● Active
$0.11
$-0.05(-30.00%)
Market Cap$45505675
P/E Ratio—
52W High$0.3468
52W Low$0.10086
Paradigm Biopharmaceuticals Limited (PBIGF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · PBIGF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-06 | 2024-06 | 2023-06 | 2022-06 | 2021-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.05M | $0.07M | $0.00M | $0.08M | $0.02M |
| Cost of Revenue | $0.07M | $0.01M | $0.02M | $0.14M | $0.10M |
| Gross Profit | ($0.02M) | $0.06M | $0.03M | ($0.06M) | ($0.08M) |
| Gross Margin %(computed) | -38.17% | 86.34% | — | -81.45% | -382.42% |
| Operating Expenses | |||||
| R&D Expenses | $17.74M | $58.33M | $52.68M | $39.01M | $33.52M |
| G&A Expenses | $0.00M | $6.22M | $6.56M | $7.93M | $8.75M |
| Total Operating Expenses | $22.87M | $65.10M | $60.07M | $47.93M | $43.31M |
| Operating Income | ($22.89M) | ($65.19M) | ($60.09M) | ($47.93M) | ($43.18M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.36M | $0.41M | $1.40M | $0.05M | $0.21M |
| Interest Expense | $0.01M | $0.01M | $0.02M | $0.03M | $0.04M |
| Income Before Tax | ($25.30M) | ($58.65M) | ($58.95M) | ($47.01M) | ($42.65M) |
| Income Tax Expense | ($6.53M) | $0.00M | ($7.04M) | ($7.76M) | ($8.35M) |
| Net Income | ($18.77M) | ($58.65M) | ($51.91M) | ($39.25M) | ($34.30M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.06 | $-0.20 | $-0.18 | $-0.16 | $-0.16 |
| Wtd Avg Shares | 314.50M | 293.28M | 289.68M | 240.96M | 212.19M |
| EBITDA | ($25.25M) | ($64.54M) | ($59.93M) | ($46.82M) | ($43.13M) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · AUD · M
Explore more Paradigm Biopharmaceuticals Limited data
About Paradigm Biopharmaceuticals Limited (PBIGF) Income Statement
Paradigm Biopharmaceuticals Limited (PBIGF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, PBIGF reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -38.17%), and net income of ($0.02B) — a net profit margin of -36014.48%.
Frequently asked questions
PBIGF · 4 questionsParadigm Biopharmaceuticals Limited (PBIGF) reported revenue of $0.00B for 2025, down 20.8% year-over-year.
PBIGF revenuePBIGF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09